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Presumptive dendritic cells (DCs) bearing the CD11c integrin and other markers have
previously been identified in normal mouse and human aorta. We used CD11c promoter–
enhanced yellow fluorescent protein (EYFP) transgenic mice to visualize aortic DCs and study
their antigen-presenting capacity. Stellate EYFP+ cells were readily identified in the aorta
and could be double labeled with antibodies to CD11c and antigen-presenting major histocompatability complex (MHC) II products. The DCs proved to be particularly abundant in
the cardiac valves and aortic sinus. In all aortic locations, the CD11c+ cells localized to the
subintimal space with occasional processes probing the vascular lumen. Aortic DCs expressed little CD40 but expressed low levels of CD1d, CD80, and CD86. In studies of antigen presentation, DCs selected on the basis of EYFP expression or binding of anti-CD11c
antibody were as effective as DCs similarly selected from the spleen. In particular, the
aortic DCs could cross-present two different protein antigens on MHC class I to CD8+ TCR
transgenic T cells. In addition, after intravenous injection, aortic DCs could capture antiCD11c antibody and cross-present ovalbumin to T cells. These results indicate that bona
fide DCs are a constituent of the normal aorta and cardiac valves.
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Inflammation is a component of many vascular
disorders such as aortic aneurysm, giant cell arteritis, Takayasu’s disease, and atherosclerosis
(1–4). DCs carry out many innate responses and
orchestrate adaptive immunity (5). It is therefore important to assess the presence and properties of DCs in major blood vessels.
Initially, electron microscopy and labeling
for several intracellular markers were used to
demonstrate DCs in human aorta, primarily in
a subendothelial location (6–9). Ma-Krupa et al.
(10) and Pryshchep et al. (11) then used more
cell-restricted markers to identify DCs in increased numbers in human arteries, whereas
Bobryshev (12) reported increased numbers of
cells expressing S100, CD1a, and p55 markers
in the intima and adventitia during atherosclerosis. Cells bearing the CD11c integrin, which
is characteristically expressed at high levels on
DCs, were also identified in the normal aortic
intima and in atherosclerosis-prone areas in
mice (13, 14). The numbers of aortic CD11c+
cells increased with aging and atherosclerosis through a recruitment process involving
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CX3CR1 chemokine receptor and VCAM-1
(13, 15, 16).
Although abundant CD11c expression is a
well-known marker for DCs, other cell types can
express moderate levels of CD11c, including activated NK cells, some macrophages, and even
some T cells (17–21). Therefore, additional criteria are required to identify DCs in the vascular
wall in the steady state and ultimately disease, particularly the capacity of DCs to express MHC
class II and present antigens to T lymphocytes.
In this study, we found that the CD11c promoter–enhanced yellow fluorescent protein
(EYFP) transgenic mouse developed by Lindquist
et al. (22) is valuable to identify and study CD11c+
cells from the normal mouse aorta. We will report
on the location, cell surface markers, and antigenpresenting functions of DCs and also describe
their abundance in all of the cardiac valves.
© 2009 Choi et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0
Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Aortic DCs are abundant in the aortic valve and sinus
To examine the distribution of DCs in the aorta, we examined
sheet preparations by confocal microscopy. In accordance with
previous reports (13, 15), we found that the EYFP+ DCs were
primarily in the intima and in focal accumulations, i.e., in the
lesser curvature of the aortic arch and the openings of arteries,
rather than a scattered distribution in the adventitia (Fig. 2 A).
When we turned to the root of the aorta, as diagrammed in
Fig. 2 B, large numbers of DCs were found in the aortic valve
and sinus (Fig. 2 C). We then prepared cell suspensions from the
aortic valve and sinus and compared the yield of DCs relative to
suspensions from the aortic arch and descending aorta. The aortic root, i.e., valve and sinus, suspensions had more numerous
EYFP cells (Fig. 2 D, top), confirming the observations in intact
tissue (Fig. 2 C). Likewise when we studied nontransgenic
C57BL/6 mice and stained cell suspensions with anti-CD11c
antibody, the aortic root had more abundant DCs, although the
intensity of the anti-CD11c signal was much reduced relative to
the EYFP signal in transgenic mice (Fig. 2 D). Mean values for
three experiments are shown in Fig. 2 D (bottom).
The presence of DCs in normal aortic valve prompted us to
examine other normal cardiac valves. Accumulations of DCs
have been reported in valves in degenerative disease, bioprostheses, and papillary fibroelastomas (23, 24). In a single prior study
of normal aortic valves, fresh and cryopreserved tissue had no
DCs (25). However, we observed many EYFP+ DCs in the left
(mitral) and right (tricuspid) atrioventricular valves (Fig. 2 E).
These findings with CD11c-EYFP mice extend prior studies by
showing that aortic DCs are especially abundant in the root of
the aorta and all cardiac valves.
498

Aortic DCs are mainly localized in the subintimal space
To examine the position of the EYFP+ DCs in the aortic wall,
we performed confocal microscopy with simultaneous staining
for CD31 to mark the vascular endothelium (26). In addition,
the confocal images were reconstituted into three-dimensional
images using the Imaris program to gain better understanding
of the anatomical localization of aortic DCs. The DCs were
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RESULTS AND DISCUSSION
Aortic DCs are readily visualized in CD11c-EYFP
transgenic mice
The CD11c-EYFP transgenic mouse (C57BL/6 background),
in which expression of the EYFP gene is controlled by the
CD11c promoter, was developed to better visualize and characterize DCs in situ, beginning with lymphoid organs in the
steady state (22). We performed flow cytometry on aortic cell
suspensions and found that 0.25–0.5% of the cells expressed
EYFP, with the signal ranging from low to high (Fig. 1 A).
The isolated EYFP+ cells also could be stained for cell surface
CD11c and MHC class II (Fig. 1 B, top). If we isolated
CD11c+ cells from normal nontransgenic C57BL/6 mice, we
again saw clear labeling for MHC class II (Fig. 1 B, bottom),
but the signals with anti-CD11c were much weaker than those
observed with EYFP mice. When we examined whole mounts
of the aorta, brightly EYFP+ dendritic profiles were evident,
and these could be double labeled with antibodies to CD11c
and MHC class II (Fig. 1 C), two markers of typical DCs in
the steady state. However this staining required the use of
tyramide amplification (see Materials and methods). These
results indicate that the CD11c-EYFP transgenic mouse is
valuable to identify and visualize aortic DCs in cell suspensions
and in situ.

Figure 1. Visualizing aortic DCs using CD11c-EYFP transgenic
mice. (A) The presence of EYFP+ cells in aortic cell suspension from EYFP
transgenic mice. Aortic segments from EYFP transgenic mice (n = 5) were
pooled and dissociated by incubation with an enzyme mixture (see
Materials and methods) and then subjected to flow cytometric analysis.
(B) Experiments were performed as in A, but the aortic CD11c+ cells were
from nontransgenic mice (n = 3) and compared for expression of CD11c
and MHC II to aortic EYFP+ cells. (C) Immunohistochemical staining of
CD11c and MHC II in aortic sheets. Each experiment was performed at
least three times. Bars, 20 μm.
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localized beneath the endothelium (Fig. 3, A and B; and
Video 1, available at http://www.jem.org/cgi/content/full/jem
.20082129/DC1), although infrequently in the aortic sinus,
dendritic processes penetrated between endothelial cells into
the lumen (Fig. 3 A, middle, arrow; and Video 2). In all sites,
i.e., aortic root, aortic arch, and descending aorta, the bodies
of the CD11c+ DCs were located in the subintimal space, and
most of the dendritic processes extended laterally within the
subintimal areas (Fig. 3, A and B, red).

In previous studies, it has been shown that intestinal DCs
extend their dendritic processes across the epithelium to capture bacteria in lumen (27). To determine whether aortic
DCs could extend processes into the vessel lumen and capture
proteins, we applied anti-CD11c antibody to whole segments
of aorta from CD11c-EYFP mice, i.e., without tissue permeabilization using Triton X-100. Parts of some of the DCs
were stained with anti-CD11c antibody (Fig. 3 C). Next, we
injected anti-CD11c antibody i.v. to CD11c-EYFP mice and
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Figure 2. Predominant localization of aortic DCs in the aortic valve and sinus. Aortic segments from aortic sinus to diaphragm were opened longitudinally to make aortic sheets. The distribution of aortic DCs was analyzed using confocal microscopy. (A) EYFP+ DCs in the intima of the aortic arch
(top left) and openings of arterial branches (top right). Adventitial EYFP+ DCs were scattered throughout the aorta including aortic arch (bottom left) and
descending aorta (bottom right) (B) Diagram of aortic sinus. Red indicates DC-abundant areas. (C) EYFP+ DCs in aortic valve (left) and sinus (right).
(D) Flow cytometric analysis of EYFP+ cells. The mean and SD of three experiments are shown below, with the aortic cell suspension in each experiment
being from at least three mice. (E) The presence of DCs in normal cardiac valves including left (left panel) and right (right panel) atrioventricular valves.
The cardiac valves were isolated using microscissors under guidance of a dissecting microscope. The valvular sheets were mounted on glass slides and
observed by confocal microscopy. Each figure is representative of at least three experiments. Bars, 40 μm.
JEM VOL. 206, March 16, 2009
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Figure 3. The anatomical position of aortic DCs in aortic wall. After immunostaining the aortic sheet using CD31 antibody to visualize the endothelium, confocal images were taken along the Z axis to visualize all dendritic processes from each EYFP+ DC and were reconstituted to a Z stack.
(A) Reconstituted Z planes from aortic valve (top), aortic sinus (middle), and aortic arch (bottom) show that the aortic DCs are localized beneath the endothelium. A small number of DCs in the aortic sinus extend their processes into the vessel lumen (A, middle, arrow). (B) Three-dimensional images were
reconstituted using the Imaris program to better visualize the position of aortic DCs. Arrows indicate the vessel lumen side. (C) Exposure of some dendritic processes into the lumen. The aortic sheets from EYFP transgenic mice were stained with CD11c antibody without tissue permeabilization to see
whether dendritic processes could capture antibody from the lumen. The confocal images were reconstituted in three dimensions. (D) Biotinylated antiCD11c and hamster IgG control antibody were injected i.v. to CD11c-EYFP mice. After 3 h, the aortic segments were isolated, incubated with horseradish
peroxidase–conjugated streptavidin, and the stained CD11c was enhanced with Alexa Fluor 555 tyramide. (E) The elastic lamina was visualized using its
autofluorescence. The confocal images were reconstituted in three dimensions. Each figure is representative of at least three experiments. Bars, 20 μm.
500
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found that some of the DCs were stained by the injected antibody (Fig. 3 D), suggesting exposure of some aortic DC processes to the contents of the lumen.
To investigate whether DC processes extend into the tunica media, the aortic elastic lamina was visualized using its
autofluorescence. We found that the DC processes were anchored to the elastic lamina and rarely penetrated the internal
elastic lamina (Fig. 3 E and Video 3, available at http://www
.jem.org/cgi/content/full/jem.20082129/DC1). These observations indicate a primarily subendothelial location of aortic DCs with some exposure to the blood stream.

Aortic CD11c+ DCs cross-present antigens
on MHC class I products
Although there have been several morphological analyses of
normal aortic CD11c+ cells, there has been no functional evidence to show that these cells can present antigens to T lymphocytes, including a property that is well developed in some
DCs, which is cross-presentation of proteins on MHC class I to
CD8+ T cells. To assess this, we first worked out assay conditions for antigen presentation using CD8+ TCR transgenic T
cells as reporters for cross-presentation by splenic DCs. As is

Figure 4. Comparison of cell surface markers of aortic and splenic DCs. Aortic and spleen cell suspensions from transgenic mice (n = 5) was
stained with antibodies to each surface marker as shown. Each figure is representative of at least three experiments.
JEM VOL. 206, March 16, 2009
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Aortic and splenic DCs have similar but not
identical phenotypes
To phenotype aortic DCs, we prepared cell suspensions from
aorta and spleen of EYFP transgenic mice and double labeled
for CD11c and various markers. Aortic DCs lacked CD40,
but expressed low levels of CD1d, CD80, and CD86, indicating their immature status (Fig. 4, top). Splenic EYFP+
DCs had slightly higher amounts of CD1d, CD40, and CD80
when compared with aortic DCs (Fig. 4, bottom). We also
analyzed the phenotype of DCs from aorta and spleen of
nontransgenic mice and assessed this same panel of markers.
Again aortic and spleen DCs were similar in phenotype,
with spleen DCs expressing more CD1d, CD40, and CD80,
although still not in high amounts (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20082129/DC1).
Together, these findings indicate that aortic DCs are in an
immature state with little or no expression of costimulatory molecules.

evident from Fig. S2 A (available at http://www.jem.org/cgi/
content/full/jem.20082129/DC1), splenic DCs presented
OVA protein at relatively low doses (60–200 μg/ml) to OT-I
transgenic T cells. In contrast, when we studied presentation of
the mouse malaria circumsporozoite (CS) protein (CSP) to
CSP-specific CD8+ TCR transgenic T cells (YA26), higher
concentrations of protein were required than with the OVAspecific OT-I T cells (Fig. S2 B). Likewise, when we used specific peptide as antigen, the OT-1 transgenic T cells were at
least 100 times more sensitive than YA26 T cells to antigen in
the presence of DCs. All OT-1 cells entered cell cycle in response to 1 pM of peptide, whereas YA26 T cells required 1
nM (Fig. 5 A). With both TCR transgenic T cells, if the DCs
were fixed with formaldehyde before testing, presentation of
protein antigen, but not preprocessed peptide, was ablated, indicating that our protein preparations were not significantly
contaminated with active peptide (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20082129/DC1). We also
assessed the importance of DC dose and time of culture for
cross-presentation to CD8+ TCR transgenic T cells. A DC to
T cell ratio of 1:6 induced proliferation (two to four cycles of
division) in the culture within 3–4 d (Fig. S4). Therefore, OT-I
cells are much more sensitive than a T cell clone specific for an
important microbial protein and capable of mediating protective anti–mouse malaria immunity in vivo (28).
Using these assay conditions, we first tested aortic CD11c+
cells from normal C57BL/6 (B6) mice (n = 6) isolated on
CD11c MACS beads. However, the CD11c-enriched aortic
cells only induced weak proliferation of OT-I and OT-II
cells (unpublished data). When we enumerated DCs in cells
isolated with MACS beads, the DC purity was <10%. To increase the purity of aortic CD11c+ cells, we used CD11cEYFP transgenic mice. After dissociating the aortic tissue
from groups of 10 mice in each experiment, EYFP+ cells
were isolated by FACS sorting. From an 8-wk-old adult
mouse, we typically isolated ⵑ1,500 EYFP+ cells from one
aortic segment, i.e., from aortic sinus to thoracic aorta inclusive. When the isolated EYFP+ cells were used to present
OVA to OT-I and OT-II T cells, we observed strong proliferative responses with most of the T cells entering cell cycle
and undergoing several divisions in 4 or 5 d (Fig. 5 B).
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Figure 5. Antigen presentation to T cells by aortic DCs. (A) Comparison between OT-1 and YA26 TCR transgenic CD8+ T cells. The indicated concentrations of OT-1 peptide (SIINFEKL) or CS peptide (SYVPSAEQI) were added to each T cell with or without splenic DCs. After 4 d, T cell proliferation was
analyzed by CFSE dilution. (B) Presentation to OVA-specific TCR transgenic T cells. Aortic and splenic EYFP+ and EYFP⫺ cells were isolated from EYFP transgenic mice (n = 10) by FACS sorting. CD8+ OT-I and CD4+ OT-II cells were isolated using Dynabeads. 200 μg/ml OVA protein was added to the DC–T cell
cocultures. Proliferation of OT-I and OT-II cells was evaluated by CFSE dilution on the FACS. The right shows the mean and SD of three experiments.
(C) Presentation to YA26 T cells. Aortic and splenic CD11chigh CD3⫺ CD19⫺ DX5⫺ cells were isolated using FACS sorting and YA26 T cells with Dynabeads.
500 μg/ml CSP was added to the DC–T cell cocultures. Proliferation of CSP-specific TCR transgenic T cells was evaluated by CFSE dilution. The right shows
the mean and SD of three experiments. (D) 5 mg OVA was injected i.v. to CD11c-EYFP (n = 10) mice. After 20 h, the aortic cell suspensions were prepared
and sorted to isolate EYFP+ and EYFP⫺ cells. Spleen EYFP+ and EYFP⫺ cells were also isolated from the mice. The cells were added to OT-1 T cells at ratio of
1:3. After 3 d, T cell proliferation was analyzed by CFSE dilution. This result is representative of two independent experiments.
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turbulent flow including the aortic valve, sinus, lesser curvature of the aortic arch, and openings of arterial branches. In
this study, we find that these DCs can effectively cross-present
i.v.-injected OVA to T cells. Turbulent flow may allow DCs
in the aorta and cardiac valves to capture disease-related pathogens and proteins and present these to T cells.
MATERIALS AND METHODS
Mice. CD11c-EYFP transgenic mice were a gift of M.C. Nussenzweig, N.
Anandasabapathy, and J. Idoyaga (The Rockefeller University, New York, NY).
We used C57BL/6 (Taconic), BALB/c (Taconic), and C×B6 F1 (Harlan) mice.
Mice were maintained under specific pathogen-free conditions and fed a normal
mouse diet ad libitum. Mouse protocols were approved by the Institutional Animal Care and Use Committee of The Rockefeller University.
Antibodies and reagents. Antibodies to cell surface markers were CD11c,
MHC II, CD31, CD80, CD86, CD1d, CD40, and CD11b (all obtained from
BD). Dynabeads were obtained from Invitrogen. Biotinylated antibodies to
CD11c and MHC class II were obtained from BD. The tyramide signal amplification kit was obtained from Invitrogen. OVA protein was obtained from
the Seikagaku Corporation.
Aortic single cell preparations and flow cytometric analysis. Aortic
single cells were prepared using previous methods with minor modifications
(16). In brief, after careful removal of the perivascular fat and cardiac muscle
tissues, using microscissors under a dissecting microscope, single cell suspensions from aortic segments, including aortic sinus with valve or aortic arch and
thoracic aorta, were prepared by incubation with an enzyme mixture containing 450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml hyaluronidase, and 60 U/ml DNase in modified Dulbecco’s PBS with calcium and
magnesium for 90 min at 37°C with gentle shaking. Splenic single cell suspensions were prepared by incubation with 400 U/ml collagenase d at 37°C for
30 min. After blocking Fc receptors using culture supernatant of 2.4G2 hybridoma, the cells were stained with the indicated fluorochrome-conjugated
antibodies. We used a FACS Caliber instrument (BD), and analyzed flow cytometric data with FlowJo software (Tree Star, Inc).
En face immunostaining and confocal microscopic analysis. The
aorta was perfused with 4% ice-cold paraformaldehyde in PBS via the left
ventricle. After removing perivascular tissues, the segments of aortic sinus,
aortic arch, and thoracic aorta were opened longitudinally and further fixed in
4% paraformaldehyde at 4°C for 30 min. After permeabilization using 0.2%
Triton X-100, staining for CD11c, MHC II, and CD31 was performed using
the Tyramide amplification (TSA) kit (Invitrogen) according to the manufacturer’s protocol. To stain DC processes exposed to the vessel lumen, we omitted the permeabilization of aortic segments with 0.2% Triton X-100. After
staining, the aortic segments were mounted on glass slides with aqueous
mounting medium. For in vivo CD11c staining, 15 μg of biotinylated antiCD11c antibody was injected i.v. to CD11c-EYFP mice. After 3 h, the aorta
was collected and incubated with 3% H2O2 and TSA blocking buffer to remove endogenous peroxidase activity and block nonspecific antibody binding. Then the aorta was incubated with horseradish peroxidase–conjugated
streptavidin for 1 h. After washing with PBS, the stained CD11c was visualized using Alexa Fluor 555 tyramide. The confocal images of en face immunostaining were obtained with an inverted laser scanning microscope (510 Meta;
Carl Zeiss, Inc.). All confocal sections were taken along the Z axis to visualize
all processes from each DC. We also used the Imaris program (Bitplane) to
perform three-dimensional reconstitution of the confocal images taken along
the Z axis.
Presentation to OVA-specific TCR transgenic T cells. In the case of
CD11c-EYFP transgenic mice, the EYFP-positive and -negative cells were
isolated from single cell suspensions of aorta and spleen using FACS sorting
(FACS Vantage; BD). For nontransgenic B6 mice, aortic CD11c+ and CD11c⫺
503

Downloaded from http://rupress.org/jem/article-pdf/206/3/497/825262/jem_20082129.pdf by Rockefeller University user on 18 August 2020

Because the cross-presentation of OVA to OT-I transgenic
T cells is a particularly sensitive system, we next examined another CD8+ T cell, YA26. Because the CSP-specific CD8+
TCR transgenic mouse is H-2d restricted, we isolated aortic
and splenic CD11c+ cells from BALB/c or C×B6 F1 mice by
FACS sorting. In accordance with a previous study (13), the
number of isolated DCs from these mice was ⵑ50% of that
seen with C57BL/6 mice. Nonetheless, the CD11c+ aortic
cells could induce YA26 T cell proliferation with CSP, whereas
CD11c⫺ cells could not (Fig. 5 C). Fig. 5 (B and C, right)
shows means from three experiments using aortic DCs as effective antigen-presenting cells, including cross-presentation.
We next examined whether the aortic DCs could crosspresent blood-borne protein antigen to T cells. 5 mg OVA was
injected i.v. and, after 20 h, the aortic EYFP+ and EYFP⫺ cells
were isolated by FACS sorting. Splenic EYFPhigh and EYFP⫺
cells were also isolated in parallel. When the isolated DCs were
mixed with OT-1 cells for 3 d, the EYFP+ aortic DCs effectively
induced the proliferation of OT-1 cells (Fig. 5 D), indicating that
aortic DCs can take up and cross-present protein antigen from
the blood stream. We were struck by the finding that aortic DCs
seemed to capture and present OVA better than splenic DCs under our experimental conditions. We suspect that i.v. OVA is
not an optimal system to reveal the antigen capture and presenting activity of splenic DCs because OVA can be recognized by
mannose receptors that are expressed on liver sinusoidal endothelium (29, 30). If so, aortic DCs may have more ready access
to the injected OVA.
The CD11c promoter-EYFP mouse has been valuable for
visualizing DCs in situ, including lymphoid organs and lung
(22, 31). We now find that the CD11c-EYFP transgenic
mouse is valuable for identifying DCs in the aorta. The strong
EYFP stain allows for their ready identification in the subintimal space of select regions of the aorta and in all the cardiac
valves. Moreover, the EYFP fluoresence can be used to isolate
the DCs by cell sorting and to phenotype the cells to show that
they express MHC II and other markers of immature DCs.
The aortic subendothelial space is an important site for the
initiation of atherosclerosis because proatherogenic LDL particles can be generated in subendothelial spaces by enzymatic or
nonenzymatic modifications during hyperlipidemia (32, 33).
Our results that DCs are in subintimal space and capture proteins from the blood stream suggest that these cells should also
be considered in generating inflammation and even immunity
in atherosclerosis-prone areas. DCs, for example, might present lipids to NKT cells leading to cytokine production and
cytotoxicity (34), and DCs appear to have a specialized endocytic system in which internalized substrates are not totally catabolized but, instead, peptides are salvaged for presentation to
T cells (35).
Importantly, we verify that aortic CD11c+ cells are effective antigen-presenting cells, as is characteristic of DCs. DCs
capture invading pathogens to generate resistance to infection,
and they contribute to immune tolerance, making these cells
an important target in studying pathogenesis and prevention of
disease (36). Aortic DCs are mainly localized in areas having

Cross-presentation to malaria CSP-specific TCR transgenic T cells.
The CSP of Plasmodium yoelii–specific TCR transgenic mice and the plasmid
for the CSP expression have been previously described (37, 38). After induction of CSP expression in Escherichia coli (BL-21), His-tagged CSP was isolated
using Ni-NTA and then subjected to FPLC to obtain high protein purity
without contaminating endotoxin. The protein buffer was then exchanged
for serum-free RPMI1640 medium using a Centricon (Millipore). Aortic and
splenic CD11chigh CD3⫺ CD19⫺ DX5⫺ DCs from C×B6 F1 mice were isolated by FACS sorting. The CSP-specific CFSE-labeled CD8+ T cells were
negatively selected by excluding B220+, F4/80+, NK1.1+, I-Ad+, and CD4+
cells using anti–rat IgG Dynabeads (Invitrogen) and mixed with isolated DCs
and antigens including protein and peptide for 4 d as indicated in the results.
In vivo OVA presentation. 5 mg OVA was injected i.v. to CD11c-EYFP
mice. After 20 h, the aortic segments were dissociated by enzyme mixture
(450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml hyaluronidase,
and 60 U/ml DNase), and the EYFP+ and EYFP⫺ cells were isolated by FACS
sorting. The isolated cells were mixed with OT-1 cells at ratio of 1:3. After
3 d, T cell proliferation was analyzed by CFSE dilution.
Online supplemental material. Fig. S1 shows the comparison of cell surface markers of aortic and splenic endogenous CD11c+ DCs. Fig. S2 demonstrates that OT-I cells can respond to relatively low doses of OVA presented
by splenic DCs when compared with mouse malaria CSP-specific TCR transgenic CD8+ T cells. Fig. S3 indicates that the OVA and CSP preparations were
not contaminated with active peptides. Fig. S4 shows the importance of DC
dose and culture time for cross-presentation. Video 1 shows the subintimal localization of aortic DCs. Video 2 shows that some DCs infrequently have dendritic process extending to aortic lumen. Video 3 shows that the DC processes
are localized on the surface of elastic lamina. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20082129/DC1.
The authors are grateful to Judy Adams for help with the manuscript. We thank
Klara Velinzon for FACS sorting. We also thank Janelle Kuroiwa for providing OT-I
and OT-II mice and Niroshana Anandasabapathy and Juliana Idoyaga for providing
CD11c-EYFP mice.
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